More Neuren Pharmaceuticals Limited news
Neuren Pharmaceuticals LimitedASX: NEU

Results of Phase 2 trial in moderate to severe TBI

Apr 25, 2016 at 11:39 PM EDT · Issued by Neuren Pharmaceuticals Limited

Filed with ASX · Apr 25, 2016 at 11:39 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/results-of-phase-2-trial-in-moderate-to-severe-tbi

Neuren Pharmaceuticals Limited on 6ix

Earlier from Neuren Pharmaceuticals

  • First subject commences Neurens Rett syndrome Phase 2 trialApr 7, 2016
  • Neuren awarded Rett Syndrome trial grantMar 30, 2016
  • Trial of Second Neuren Drug Motiva to be InitiatedMar 30, 2016
  • Neuren Starts Phase II Trial of NNZ2566Mar 30, 2016
  • Grant funding for TFF oncology programMar 30, 2016

Later from Neuren Pharmaceuticals

  • Grant of new patent for Autism Spectrum DisordersJun 22, 2016
  • Neuren presents at Rettsyndrome.org 2016 Research SymposiumJun 24, 2016
  • Neuren expands Phase 2 Rett syndrome pediatric trialAug 24, 2016
  • Neuren receives $0.9m from exercise of last expiring optionsOct 27, 2016
  • Neuren completes enrolment in Rett syndrome Phase 2 trialNov 13, 2016
All Neuren Pharmaceuticals news releases↗

Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.

Follow Neuren Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer